In a pilot phase II study (ClinicalTrials.gov identifier: NCT02507492), two patients with POMC deficiency were treated with setmelanotide.61 The patients experienced not only a sustainable reduction in hunger but also significant weight loss (51.0 kg at week 42 in the first patient and 20.5 kg at week 12 in the second patient). This evidence concerns the gene POMC and hyperinsulinemic hypoglycemia, familial, 4.